Get the Stockscreener App
2.30
1.71%
-0.04
Tempest Therapeutics Inc stock is traded at $2.30, with a volume of 62,418.
It is down -1.71% in the last 24 hours and up +3.14% over the past month.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
See More
Previous Close:
$2.34
Open:
$2.34
24h Volume:
62,418
Relative Volume:
0.37
Market Cap:
$30.74M
Revenue:
-
Net Income/Loss:
$-43.10M
P/E Ratio:
-0.2366
EPS:
-9.7212
Net Cash Flow:
$-36.82M
1W Performance:
+0.44%
1M Performance:
+3.14%
6M Performance:
-58.14%
1Y Performance:
-56.59%
1-Day Range:
$2.25
$2.46
1-Week Range:
$2.13
$2.46
52-Week Range:
$1.20
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415-798-8589
Address
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
2.28 | 31.55M | 0 | -43.10M | -36.82M | -9.7212 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.31 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
763.61 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
722.13 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.36 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
291.71 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-22-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Apr-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-10-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-14-24 | Initiated | Scotiabank | Sector Outperform |
| Feb-08-24 | Initiated | Jefferies | Buy |
Tempest Therapeutics Inc Stock (TPST) Latest News
Earnings Recap: Is Tempest Therapeutics Inc stock a value trap2025 EndofYear Setup & Smart Swing Trading Techniques - baoquankhu1.vn
TPST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tempest Therapeutics, Inc. (TPST) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - FinancialContent
EX-99.1 - SEC.gov
Tempest Therapeutics reports complete response in myeloma trial - Investing.com
Tempest Therapeutics Advances TPST-2003 CAR-T with Strong Data - TipRanks
Tempest reports 100% ORR in evaluable TPST-2003 patients, plans U.S. registrational study in 2026 - TradingView
Tempest Therapeutics (TPST) reveals 100% response in TPST-2003 multiple myeloma study - Stock Titan
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Bitget
Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned - Stock Titan
Tempest Therapeutics reports complete response in myeloma trial By Investing.com - Investing.com Canada
Why Tempest Therapeutics Inc. stock could outperform in 2025Weekly Profit Recap & Free Community Supported Trade Ideas - mfd.ru
How Tempest Therapeutics Inc. stock reacts to global recession fearsMarket Sentiment Report & AI Enhanced Execution Alerts - mfd.ru
Is Tempest Therapeutics Inc.’s growth already priced inBuy Signal & Daily Oversold Bounce Ideas - mfd.ru
What catalysts could drive Tempest Therapeutics Inc. stock higher2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Will Tempest Therapeutics Inc. stock recover after earningsM&A Rumor & Advanced Swing Trade Entry Plans - mfd.ru
TPST Should I Buy - Intellectia AI
How cyclical is Tempest Therapeutics Inc.’s revenue streamEarnings Performance Report & Smart Swing Trading Techniques - mfd.ru
Tempest Therapeutics Highlights Partner-Funded CAR-T Oncology Pipeline - The Globe and Mail
Tempest lays out strategic plan to advance recently acquired dual-targeting CAR-T assets - marketscreener.com
Tempest Therapeutics outlines plans for acquired CAR T assets - bioworld.com
Tempest Therapeutics, Inc. Updates on Oncology Pipeline and Clinical Progress - TradingView
Partner-funded China trials anchor Tempest’s new CAR-T push - Stock Titan
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - The Manila Times
Key facts: Tempest Therapeutics announces management changes; issues warrants - TradingView
Tempest Therapeutics Signs Warrant Agreement With Computershare - TradingView
Tempest Therapeutics (NASDAQ: TPST) closes CAR T acquisition and names new CEO - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - The Manila Times
Tempest Therapeutics completes acquisition of CAR-T assets By Investing.com - Investing.com Nigeria
Tempest Therapeutics completes acquisition of CAR-T assets - Investing.com
Tempest Therapeutics Closes All-Stock Transaction to Acquire Next-Generation CAR-T Assets and Appoints Matt Angel as CEO - Quiver Quantitative
Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan
Tempest Therapeutics (TPST) Price Target Increased by 22.22% to 11.22 - Nasdaq
Tempest Therapeutics Announces New Leadership and Acquisition - MSN
Will Tennessee Valley Authority benefit from AI trendsMarket Sentiment Summary & Weekly High Momentum Picks - baoquankhu1.vn
What’s the outlook for Tempest Therapeutics Inc.’s sectorPortfolio Gains Report & Consistent Return Investment Signals - mfd.ru
Tempest Therapeutics (NASDAQ: TPST) wins approval for rights plan, share issuance and equity pool - Stock Titan
Investment Report: Is Tempest Therapeutics Inc stock a value trapJuly 2025 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
Aug Decliners: Is Tempest Therapeutics Inc stock a top performer YTD2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tempest Therapeutics stock surges after H.C. Wainwright upgrade By Investing.com - Investing.com Australia
Tempest Therapeutics stock surges after H.C. Wainwright upgrade - Investing.com
H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target - Investing.com India
HC Wainwright & Co. Upgrades Tempest Therapeutics (TPST) - Nasdaq
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - The Manila Times
Inflation Data: Will Tempest Therapeutics Inc stock recover after earningsJuly 2025 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Tempest Therapeutics Announces Record Date for Warrant Dividends Distribution Following Asset Purchase Agreement - Quiver Quantitative
Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan
How risky is Tempest Therapeutics Inc. stock nowCEO Change & Precise Buy Zone Tips - bollywoodhelpline.com
Will Tempest Therapeutics Inc. stock pay special dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - bollywoodhelpline.com
Tempest Therapeutics Inc Stock (TPST) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.07%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):